» Articles » PMID: 24063517

The Mutational Landscape of Chromatin Regulatory Factors Across 4,623 Tumor Samples

Overview
Journal Genome Biol
Specialties Biology
Genetics
Date 2013 Sep 26
PMID 24063517
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chromatin regulatory factors are emerging as important genes in cancer development and are regarded as interesting candidates for novel targets for cancer treatment. However, we lack a comprehensive understanding of the role of this group of genes in different cancer types.

Results: We have analyzed 4,623 tumor samples from thirteen anatomical sites to determine which chromatin regulatory factors are candidate drivers in these different sites. We identify 34 chromatin regulatory factors that are likely drivers in tumors from at least one site, all with relatively low mutational frequency. We also analyze the relative importance of mutations in this group of genes for the development of tumorigenesis in each site, and indifferent tumor types from the same site.

Conclusions: We find that, although tumors from all thirteen sites show mutations in likely driver chromatin regulatory factors, these are more prevalent in tumors arising from certain tissues. With the exception of hematopoietic, liver and kidney tumors, as a median, the mutated factors are less than one fifth of all mutated drivers across all sites analyzed. We also show that mutations in two of these genes, MLL and EP300, correlate with broad expression changes across cancer cell lines, thus presenting at least one mechanism through which these mutations could contribute to tumorigenesis in cells of the corresponding tissues.

Citing Articles

Exploring novel biomarkers and immunotherapeutic targets for biofeedback therapies to reveal the tumor-associated immune microenvironment through a multimetric analysis of kidney renal clear cell carcinoma.

Wang G, Huang J, Chen H, Jiang C, Jiang L, Feng W Discov Oncol. 2025; 16(1):311.

PMID: 40080320 PMC: 11906931. DOI: 10.1007/s12672-025-02090-5.


Decoding functional impact of epigenetic regulator mutations on ligand-receptor interaction perturbations for evaluation of cancer immunotherapy.

Shi A, Lin C, Lyu J J Cell Mol Med. 2024; 28(18):e70009.

PMID: 39323009 PMC: 11424496. DOI: 10.1111/jcmm.70009.


Identification of a signature of histone modifiers in kidney renal clear cell carcinoma.

Huang Y, Yang Z, Tang Y, Chen H, Liu T, Peng G Aging (Albany NY). 2024; 16(12):10489-10511.

PMID: 38888515 PMC: 11236308. DOI: 10.18632/aging.205944.


Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.

Keller P, Adams E, Wu R, Cote A, Arora S, Cantone N Cancer Res. 2024; 84(15):2501-2517.

PMID: 38833522 PMC: 11292196. DOI: 10.1158/0008-5472.CAN-24-0398.


Identification and validation of the clinical prediction model and biomarkers based on chromatin regulators in colon cancer by integrated analysis of bulk- and single-cell RNA sequencing data.

Ma Y, Fang F, Liao K, Zhang J, Wei C, Liao Y Transl Cancer Res. 2024; 13(3):1290-1313.

PMID: 38617504 PMC: 11009811. DOI: 10.21037/tcr-23-1886.


References
1.
Seo J, Ju Y, Lee W, Shin J, Lee J, Bleazard T . The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012; 22(11):2109-19. PMC: 3483540. DOI: 10.1101/gr.145144.112. View

2.
Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

3.
Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen E . SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res. 2005; 65(9):3542-7. DOI: 10.1158/0008-5472.CAN-04-3554. View

4.
Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

5.
Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View